EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Real-World Efficacy of Cadonilimab Plus Chemotherapy as Second-Line Therapy in Immunotherapy-Pretreated Advanced HER2 Negative Gastric or Gastroesophageal Junction Cancer

Zeyu Liu, Yuxiao Lu, Ming Li, Jinyu Xiang iD, Ping Sun, Aina Liu

Drug Design, Development and Therapy · 2025

DOI: 10.2147/dddt.s548735 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Zeyu Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, People's Republic of China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Esophagogastric Junction, Esophageal Neoplasms, Immunotherapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsEsophagogastric JunctionEsophageal NeoplasmsImmunotherapyAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedHumansFemaleMaleRetrospective StudiesMiddle AgedErb-b2 Receptor Tyrosine KinasesAgedAdult

Stichwörter der Autor:innen

PD-1/CTLA-4 bispecificadvanced gastroesophageal junction cancercadonilimabefficacysafetysecond-line treatment

Substanzen

Erb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedERBB2 protein, human

Autor:innen und Institutionen

  • Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, 264000, People's Republic of China.

ORCID-Profile: Jinyu Xiang

Zitieren

APA

Liu, Z., Lu, Y., Li, M., Xiang, J., Sun, P., & Liu, A. (2025). Real-World Efficacy of Cadonilimab Plus Chemotherapy as Second-Line Therapy in Immunotherapy-Pretreated Advanced HER2 Negative Gastric or Gastroesophageal Junction Cancer. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s548735

Vancouver

Liu Z, Lu Y, Li M, Xiang J, Sun P, Liu A. Real-World Efficacy of Cadonilimab Plus Chemotherapy as Second-Line Therapy in Immunotherapy-Pretreated Advanced HER2 Negative Gastric or Gastroesophageal Junction Cancer. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s548735

BibTeX
@article{Liu2025,
  author = {Liu, Zeyu and Lu, Yuxiao and Li, Ming and Xiang, Jinyu and Sun, Ping and Liu, Aina},
  title = {Real-World Efficacy of Cadonilimab Plus Chemotherapy as Second-Line Therapy in Immunotherapy-Pretreated Advanced HER2 Negative Gastric or Gastroesophageal Junction Cancer},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  doi = {10.2147/dddt.s548735}
}
Kostenlos starten →